Stoke Therapeutics (STOK) Expected to Announce Earnings on Wednesday

Key Points

• Stoke Therapeutics is set to release its Q2 2025 earnings results on August 6th, with analysts predicting a loss of ($0.09) per share and revenue of $31.51 million.
• Insider Barry Ticho recently sold 6,471 shares at $10.03 each, marking a 20.06% decrease in his position within the company.
• Several institutional investors, including Goldman Sachs, have increased their holdings, indicating growing interest in Stoke Therapeutics, which currently has a consensus buy rating from analysts.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $31.51 million for the quarter.

Stoke Therapeutics Price Performance

Shares of STOK traded up $0.06 during midday trading on Friday, hitting $12.91. The stock had a trading volume of 426,084 shares, compared to its average volume of 788,734. Stoke Therapeutics has a 1 year low of $5.35 and a 1 year high of $16.15. The firm has a market cap of $704.89 million, a PE ratio of 16.34 and a beta of 1.14. The stock's 50 day moving average is $11.61 and its 200 day moving average is $9.82.

Wall Street Analyst Weigh In

STOK has been the topic of several recent analyst reports. HC Wainwright reduced their target price on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Jefferies Financial Group started coverage on shares of Stoke Therapeutics in a research report on Friday, July 18th. They set a "buy" rating and a $30.00 target price on the stock. Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Finally, Needham & Company LLC restated a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $25.80.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Barry Ticho sold 6,471 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total transaction of $64,904.13. Following the completion of the sale, the insider directly owned 25,782 shares in the company, valued at approximately $258,593.46. The trade was a 20.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 9.50% of the company's stock.

Institutional Trading of Stoke Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of STOK. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Stoke Therapeutics by 5.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company's stock valued at $162,000 after purchasing an additional 1,149 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Stoke Therapeutics by 21.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company's stock worth $11,053,000 after purchasing an additional 293,072 shares during the last quarter. Finally, Jane Street Group LLC boosted its position in shares of Stoke Therapeutics by 125.2% during the 1st quarter. Jane Street Group LLC now owns 26,978 shares of the company's stock valued at $179,000 after acquiring an additional 15,001 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.